The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View gvhd content recommended for you
Ibrutinib in patients with steroid-refractory cGvHD: Results from a real-world analysis
|
A multicenter, real-world observational study assessed the safety and efficacy of ibrutinib, a BTK inhibitor, in 270 patients with SR-cGvHD from 19 centers in the US.1 Results from this analysis were published in Blood Advances by Pidala et al.1 |
| Key learnings |
| Among the 131 evaluable patients, the ORR, CR, and PR rates were 45%, 3%, and 42%, respectively, with a median DOR of 15 months. |
| At a median follow-up of 30.5 months, the 6-month and 12-month FFS rates were 59% and 41%, respectively, and the 6-month and 12-month OS rates were 93% and 87%, respectively. |
| In the multivariable analysis, increased age (HR, 1.01; 95% CI, 1.0–1.02; p = 0.033), higher baseline prednisone dose (HR, 1.92; 95% CI, 1.09–3.38; p = 0.032), and lung involvement (HR, 1.58; 95% CI, 1.1–2.28; p = 0.016) were associated with worse FFS. |
| Results from this study confirm the safety and efficacy of ibrutinib in a real-world setting in patients with SR-GvHD and highlight the factors associated with worse outcomes. |
Abbreviations: BTK, Bruton’s tyrosine kinase; cGvHD, chronic graft-versus-host disease; CI, confidence interval; CR, complete response; DOR, duration of response; FFS, failure-free survival; HR, hazard ratio; ORR, overall response rate; OS, overall survival; PR, partial response; SR-cGvHD, steroid-refractory cGvHD.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
